Reese retiring after two decades at Amgen

David Reese will retire this June after a 21-year tenure at Amgen Inc. (NASDAQ:AMGN), which he began in 2005 as a clinical development leader in oncology, rising to become EVP of R&D in 2018, a role he held for five years. In 2023, Reese took on the newly created role of CTO, with a focus on early adoption of technology and AI in R&D and elsewhere in the organization. 

As Reese readies to depart, his successor as head of R&D, James Bradner, will see his role expand as he becomes EVP, R&D, AI and Data, part of what the biotech called an evolution of its organization to advance innovation at the nexus of biology, data science and technologies such as AI...